Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds - PubMed (original) (raw)
Comparative Study
doi: 10.1159/000068478.
Affiliations
- PMID: 12584433
- DOI: 10.1159/000068478
Comparative Study
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds
I Skoog et al. Dement Geriatr Cogn Disord. 2003.
Abstract
Deposition of beta-amyloid (Abeta) is an early pathogenic event in Alzheimer's disease (AD). We measured Abeta42 and Abeta40 in cerebrospinal fluid (CSF) in a population-based sample of 85-year-olds, 27 demented and 35 non-demented. During the following 3 years, 7 of the 35 non-demented individuals had developed dementia, while 28 remained non-demented. Reduced CSF levels of both Abeta42 (p = 0.001) and Abeta40 (p = 0.0001) were found in patients with manifest AD and vascular dementia at the age of 85. Non-demented individuals who developed dementia during follow-up had lower levels of CSF- Abeta42 (p = 0.003), but not CSF-Abeta40 (p = 0.96), than those who remained non-demented. The odds ratio for development of dementia was 8.2 (p = 0.027) for individuals in the lower 50th percentile of CSF-Abeta42, while none of those in the highest 33rd percentile of CSF-Abeta42 developed dementia during follow-up. There were no significant differences between carriers and non-carriers of the apolipoprotein E epsilon4 allele regarding CSF-Abeta42 or CSF-Abeta40. Our study suggests that low CSF-Abeta42 is found also in an unselected population-based sample of old demented patients and provides the first evidence of a disturbance in the metabolism of Abeta, specifically involving Abeta42, before the onset of clinical symptoms in AD.
Copyright 2003 S. Karger AG, Basel
Similar articles
- Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Lautner R, et al. JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367 - Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Mehta PD, et al. Arch Neurol. 2000 Jan;57(1):100-5. doi: 10.1001/archneur.57.1.100. Arch Neurol. 2000. PMID: 10634455 - Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F. Bousiges O, et al. J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731. J Alzheimers Dis. 2016. PMID: 26923009 - Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.
Shoji M. Shoji M. Front Biosci. 2002 Apr 1;7:d997-1006. doi: 10.2741/A826. Front Biosci. 2002. PMID: 11897565 Review. - Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.
Tang W, Huang Q, Wang Y, Wang ZY, Yao YY. Tang W, et al. J Neurol Sci. 2014 Oct 15;345(1-2):26-36. doi: 10.1016/j.jns.2014.07.015. Epub 2014 Jul 15. J Neurol Sci. 2014. PMID: 25086857 Review.
Cited by
- Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease.
Andersson E, Janelidze S, Lampinen B, Nilsson M, Leuzy A, Stomrud E, Blennow K, Zetterberg H, Hansson O. Andersson E, et al. Neurobiol Aging. 2020 Nov;95:143-153. doi: 10.1016/j.neurobiolaging.2020.07.018. Epub 2020 Jul 25. Neurobiol Aging. 2020. PMID: 32810755 Free PMC article. - Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.
Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Roher AE, et al. Biomarkers. 2009 Nov;14(7):493-501. doi: 10.3109/13547500903108423. Biomarkers. 2009. PMID: 19863188 Free PMC article. - Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.
Chou YY, Leporé N, Avedissian C, Madsen SK, Parikshak N, Hua X, Shaw LM, Trojanowski JQ, Weiner MW, Toga AW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Chou YY, et al. Neuroimage. 2009 Jun;46(2):394-410. doi: 10.1016/j.neuroimage.2009.02.015. Epub 2009 Feb 21. Neuroimage. 2009. PMID: 19236926 Free PMC article. - Fluid biomarkers in Alzheimer's disease - current concepts.
Rosén C, Hansson O, Blennow K, Zetterberg H. Rosén C, et al. Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Mol Neurodegener. 2013. PMID: 23800368 Free PMC article. Review. - Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.
Soejitno A, Tjan A, Purwata TE. Soejitno A, et al. CNS Drugs. 2015 Jun;29(6):487-502. doi: 10.1007/s40263-015-0257-8. CNS Drugs. 2015. PMID: 26187557 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical